Asthma-Chronic Obstructive Pulmonary Disease (COPD) Overlap Treatment Market Analysis 2026: Market Size, Growth Trends And Industry Outlook
Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Asthma-Chronic Obstructive Pulmonary Disease (COPD) Overlap Treatment Market Revenue Outlook: What CAGR Lies Ahead Through 2030?
The asthma-chronic obstructive pulmonary disease (COPD) overlap treatment market has experienced robust expansion in recent years. It is projected to increase from $9.44 billion in 2025 to $10.23 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.4%. The growth observed in prior periods can be attributed to the rising occurrence of smoking-related respiratory illnesses, an increase in the misdiagnosis of asthma and COPD overlap conditions, insufficient personalized treatment options in respiratory care, a surge in hospital admissions resulting from exacerbations, and a reliance on traditional inhalation therapies.
The asthma-chronic obstructive pulmonary disease (COPD) overlap treatment market size is anticipated to undergo significant expansion in the foreseeable future. It will grow to $14.27 billion by 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth anticipated during the forecast period stems from the broadened application of biologics in respiratory disease management, the increasing adoption of digital respiratory monitoring equipment, a growing need for personalized treatment plans, the expansion of home-based chronic disease management, and advancements in targeted anti-inflammatory therapies. Noteworthy trends predicted for this period encompass personalized precision therapy tailored to asthma-COPD overlap phenotypes, digital monitoring of inhaler adherence coupled with connected respiratory care, the proliferation of biologic-based treatments for eosinophilic airway inflammation, the incorporation of remote patient monitoring into chronic respiratory disease management, and a transition towards combination inhalation therapies for enhanced airway control.
Get A Free Sample Report With In-Depth Market Insights:
Asthma-Chronic Obstructive Pulmonary Disease (COPD) Overlap Treatment Market Growth Drivers: What’s Behind The Acceleration?
The increasing incidence of cases primarily attributed to smoking is anticipated to fuel the expansion of the asthma chronic obstructive pulmonary disease (COPD) overlap treatment market moving forward. Such smoking-driven cases refer to instances of respiratory illnesses, including asthma or COPD, that arise predominantly from tobacco smoking. The surge in smoking-driven cases is observed due to a growing number of individuals using tobacco products, which results in inflammation of the lungs, harm to airways, and an elevated risk of developing chronic respiratory conditions. Asthma-COPD overlap treatment addresses these smoking-driven cases by offering specific therapies that concurrently manage the combined symptoms, restrictions in airflow, and lung damage caused by tobacco consumption, thereby enhancing respiratory function and the quality of life for patients afflicted with both asthma and COPD. For example, in February 2026, the Australian Institute of Health and Welfare, an Australia-based government agency, reported that chronic obstructive pulmonary disease (COPD) contributed to 3.7% of Australia’s total disease burden in 2024 and was the fundamental cause of 7,437 deaths in 2023, equivalent to 28 deaths per 100,000 people, representing 4.1% of all deaths. Consequently, the rise in smoking cases is projected to propel the growth of the asthma COPD overlap treatment market.
Asthma-Chronic Obstructive Pulmonary Disease (COPD) Overlap Treatment Market Segment Breakdown: Which Categories Lead On Revenue?
The asthma-chronic obstructive pulmonary disease (copd) overlap treatment market covered in this report is segmented –
1) By Drug Class: Triple Therapy, Dual Therapy, Biologics, Systemic Therapies
2) By Treatment Use Case: Exacerbation Prevention In Asthma Chronic Obstructive Pulmonary Disease Overlap Phenotypes, Severe Asthma With Fixed Airflow Limitation, Chronic Obstructive Pulmonary Disease With Eosinophilic Inflammation, Post Hospital Discharge Optimization, Comorbidity Driven Management
3) By Route Of Administration: Inhalation, Oral
4) By Patient Age Group: Pediatric, Adult, Geriatric
5) By End User: Retail Pharmacy Channel, Hospitals, Pulmonology Clinics, Primary Care Centers, Other End Users
Subsegments:
1) By Triple Therapy: Inhaled Corticosteroid Long Acting Beta Agonist Long Acting Muscarinic Antagonist Combinations, Fixed Dose Combination Inhalers, Maintenance Therapy Combinations
2) By Dual Therapy: Inhaled Corticosteroid Long Acting Beta Agonist Combinations, Long Acting Beta Agonist Long Acting Muscarinic Antagonist Combinations, Add On Bronchodilator Combinations
3) By Biologics: Interleukin Five Inhibitors, Interleukin Four And Interleukin Thirteen Pathway Inhibitors, Immunoglobulin E Targeting Therapies, Monoclonal Antibody Treatments
4) By Systemic Therapies: Oral Corticosteroids, Systemic Bronchodilators, Anti Inflammatory Agents, Immune Modulating Therapies
Asthma-Chronic Obstructive Pulmonary Disease (COPD) Overlap Treatment Market Leading Companies And Competitive Benchmarking
Major companies operating in the asthma-chronic obstructive pulmonary disease (copd) overlap treatment market are Pfizer Inc., Sanofi S. A., Novartis AG, AstraZeneca PLC, GlaxoSmithKline plc, Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Grifols S. A., Sun Pharmaceutical Industries Limited, Chiesi Farmaceutici S. p. A., Kyowa Kirin Co. Ltd., Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, Theravance Biopharma Inc., Orion Corporation
View The Full Asthma-Chronic Obstructive Pulmonary Disease (COPD) Overlap Treatment Market Report:
Asthma-Chronic Obstructive Pulmonary Disease (COPD) Overlap Treatment Market Top Region By Revenue And Market Share
North America was the largest region in the asthma-chronic obstructive pulmonary disease (COPD) overlap treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma-chronic obstructive pulmonary disease (COPD) overlap treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
